retatrutide phase 2 nejm 2023 obesity trial jastreboff SURMOUNT-1 (NEJM 2022) tested tirzepatide β a dual GIP/GLP-1 receptor agonist β in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants π Retatrutide may be redefining
Pay in 4 interest-free payments of $6.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 28 - Sep 2


























